10-Q: Aardvark Therapeutics Q3: R&D Soars, PWS Trial Advances

Aardvark Therapeutics reports increased R&D spending and net losses in Q3 2025, driven by clinical trial advancements for ARD-101 and ARD-201, while maintaining a strong cash position into 2027.

Summary

• Aardvark Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, specifically targeting Bitter Taste Receptors (TAS2Rs) to alleviate hunger.
• The lead product candidate, ARD-101, has initiated a Phase 3 clinical trial (HERO) for hyperphagia associated with Prader-Willi Syndrome (PWS) in December 2024.
• The FDA has aligned with the company on a protocol amendment in October 2025 to change the minimum age of eligibility for the HERO trial from 13 to 10 years, broadening the potential patient population.
• Topline data for the HERO clinical trial is anticipated in the third quarter of 2026.
• Plans to evaluate ARD-101 in a Phase 2 clinical trial for hyperphagia associated with hypothalamic obesity (HONOR trial) have been indefinitely delayed to reallocate resources to the ARD-201 program.
• ARD-201, a planned fixed-dose combination of ARD-101's active ingredient and a DPP-4 inhibitor, will be explored in two new Phase 2 clinical trials: POWER (Prevention Of WEight Regain) and STRENGTH (Sitagliptin and TAS2R for weight Reduction with Exercise, Nutrition, and GLP-1RA Trial and Hunger assessment).
• The POWER trial is expected to initiate in the second half of 2025, with preliminary or interim data anticipated in the second half of 2026, focusing on preventing weight regain after GLP-1RA discontinuation.
• The STRENGTH trial is planned to initiate in the first half of 2026, exploring placebo-adjusted weight loss and the additive effect of ARD-201 with GLP-1RA therapy.
• Preclinical data for ARD-201 demonstrated significant weight loss (-18.8% ± 2.1% at 30 days) and improved glucose homeostasis in high-fat diet (HFD) mouse models, as well as improved weight maintenance after tirzepatide discontinuation.
• Net loss for the three months ended September 30, 2025, was $16.3 million, compared to $4.2 million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $39.993 million, compared to $11.809 million for the same period in 2024.
• Research and development (R&D) expenses increased by $9.7 million to $13.7 million for Q3 2025 (from $4.1 million in Q3 2024) and by $25.3 million to $34.6 million for the nine months ended September 30, 2025 (from $9.3 million in 2024), primarily due to clinical studies, chemistry, manufacturing and controls (CMC) for ARD-101, and increased headcount.
• General and administrative (G&A) expenses increased by $2.9 million to $4.0 million for Q3 2025 (from $1.0 million in Q3 2024) and by $5.5 million to $9.4 million for the nine months ended September 30, 2025 (from $3.9 million in 2024), driven by increased headcount, facilities, and public company operating costs.
• Cash, cash equivalents, and short-term investments totaled $126.4 million as of September 30, 2025, which is believed to be sufficient to fund projected operations into 2027.
• A material weakness in internal control over financial reporting was identified at December 31, 2024, related to a lack of controls in the financial reporting process, including segregation of duties and documentation of formalized procedures; remediation efforts are underway.

Sentiment

Score: 6

Explanation: The sentiment is cautiously optimistic. While significant net losses and increased expenses are negatives, they are expected for a clinical-stage biotech advancing multiple programs, including a pivotal Phase 3 trial. The strong cash position into 2027 provides a good runway. Promising preclinical data for ARD-201 and strategic shifts to more focused trials are positive developments. However, the inherent high risks of drug development, the indefinite delay of one trial, and the identified material weakness in internal controls temper the overall sentiment.

Positives

• Initiation of the potentially pivotal Phase 3 HERO clinical trial for ARD-101 in hyperphagia associated with Prader-Willi Syndrome (PWS) in December 2024.
• FDA alignment on a protocol amendment in October 2025 to lower the minimum age of eligibility for the HERO trial from 13 to 10 years, expanding the potential patient population.
• Commencement of the HERO Open Label Extension (OLE) trial and establishment of first clinical sites in Australia, indicating broader clinical reach.
• Promising new preclinical data for ARD-201 demonstrating significant weight loss (-18.8% ± 2.1% at 30 days) and improved glucose homeostasis in diet-induced obesity (DIO) mice.
• ARD-201 preclinical studies showed improved weight maintenance compared to vehicle control after transient tirzepatide (GLP-1RA) treatment, and similar weight maintenance to continued high-dose tirzepatide, suggesting potential in preventing weight regain.
• ARD-201 preclinical data indicated significant fat mass reduction without significant lean body mass reduction, a favorable outcome in weight management.
• Strategic decision to replace the EMPOWER trial with two more focused Phase 2 trials (POWER and STRENGTH) for ARD-201, aiming for clearer and more precise clinical benefit detection.
• Strong cash, cash equivalents, and short-term investments totaling $126.4 million as of September 30, 2025, providing a projected operational runway into 2027.
• Successful completion of an Initial Public Offering (IPO) in February 2025, generating net proceeds of approximately $87.5 million.
• Increased interest and dividend income of $1.351 million for Q3 2025 and $4.014 million for the nine months ended September 30, 2025, due to higher invested cash balances.

Negatives

• Significant increase in net loss to $16.3 million for the three months ended September 30, 2025, compared to $4.2 million for the same period in 2024.
• Accumulated deficit reached $98.3 million as of September 30, 2025, reflecting ongoing operational losses.
• Substantial increase in research and development (R&D) expenses by $9.7 million for Q3 2025 and $25.3 million for the nine months ended September 30, 2025.
• General and administrative (G&A) expenses rose significantly by $2.9 million for Q3 2025 and $5.5 million for the nine months ended September 30, 2025, partly due to public company costs.
• Indefinite delay of the Phase 2 clinical trial (HONOR trial) for ARD-101 in hypothalamic obesity, diverting resources from a previously planned program.
• Identified a material weakness in internal control over financial reporting at December 31, 2024, due to a lack of controls, segregation of duties, and formalized processes, which could impact financial reporting accuracy.
• No products approved for sale and no revenue generated to date, indicating continued reliance on financing for operations.
• Unreimbursed costs of $1.4 million from related party Aardwolf Therapeutics, Inc. (including a $1.0 million convertible promissory note) have been deemed uncollectible and fully written off.

Risks

• Limited operating history and no products approved for commercial sale make it difficult to evaluate business success and future viability.
• Substantial additional financing will be required to achieve goals; failure to obtain capital could force delays, reductions, or termination of product development programs and commercialization efforts.
• Business is heavily dependent on the successful development, regulatory approval, and commercialization of the lead product candidate, ARD-101.
• The regulatory approval processes are lengthy, time-consuming, and inherently unpredictable; there is no guarantee of obtaining required regulatory approval for product candidates.
• Preclinical and clinical drug development is a lengthy and expensive process with uncertain timelines and outcomes, and earlier results may not be predictive of future trial results.
• Difficulty identifying and enrolling patients with low-prevalence disorders like PWS could delay clinical development activities.
• Clinical trials may fail to demonstrate safety and efficacy, or serious adverse events or side effects may be identified, preventing or delaying regulatory approval and commercialization.
• Reliance on third parties to conduct preclinical studies, clinical trials, and manufacturing introduces risks of non-performance, delays, increased costs, or unsuccessful development programs.
• Inability to obtain, maintain, and enforce intellectual property protection could allow competitors to make, use, or sell substantially similar product candidates.
• A material weakness in internal control over financial reporting has been identified; failure to remediate could adversely affect investor confidence and stock value.
• Substantial competition from major pharmaceutical and biotechnology companies may result in smaller commercial opportunities or competitors developing products more successfully.
• Disruptions at the FDA, SEC, and other government agencies (e.g., funding shortages, shutdowns, layoffs) could negatively impact business operations, regulatory interactions, and access to capital.
• Changes in methods of product candidate manufacturing or formulation may result in additional costs or delays.
• May not be successful in efforts to identify or discover additional product candidates in the future.
• Orphan Drug Designation for ARD-101 may not be maintained or provide sufficient exclusivity, limiting potential profitability.
• Breakthrough Therapy designation, if granted, may not lead to a faster development or regulatory review or approval process.
• Conducting clinical trials outside the United States carries risks, and data from such trials may not be accepted by the FDA or comparable foreign regulatory authorities.
• Even if product candidates receive regulatory approval, ongoing regulatory obligations and continued review may result in significant additional expense, labeling restrictions, or market withdrawal.
• Expending limited resources to pursue a particular product candidate or indication may cause the company to fail to capitalize on more profitable opportunities.
• Obtaining and maintaining regulatory approval in one jurisdiction does not guarantee success in other jurisdictions.
• Relationships with customers, physicians, and third-party payors are subject to federal and state healthcare fraud and abuse laws, false claims laws, and other regulations; non-compliance could lead to substantial penalties.
• Recently enacted legislation, future legislation, and other healthcare reform measures may increase the difficulty and cost of obtaining marketing approval and affect pricing.
• Foreign data protection laws, including the EU GDPR and UK GDPR, impose stringent requirements and potential fines for non-compliance.
• Product liability lawsuits against the company could cause substantial liabilities and limit commercialization of any developed products.
• Significant disruptions of information technology systems or data security incidents could result in significant financial, legal, regulatory, business, and reputational harm.
• If market opportunities for any product candidates are smaller than estimated, revenue may be adversely affected.
• The increasing use of social media platforms presents new risks and challenges, including potential non-compliance with regulations and reputational harm.
• An active and liquid trading market for common stock may not develop or be maintained, impairing the ability to sell shares.
• Stock price may be volatile, resulting in substantial losses for investors.
• Quarterly and annual operating results may fluctuate significantly or fall below expectations, causing stock price decline.
• No anticipated dividends on capital stock; capital appreciation, if any, will be the sole source of gain.
• Board of directors is authorized to issue and designate shares of preferred stock without stockholder approval, potentially diluting common stock value.
• Principal stockholders and management own a significant percentage of common stock and can control matters subject to stockholder approval.
• Anti-takeover provisions in charter documents and Delaware law could prevent or delay an acquisition beneficial to stockholders.
• Exclusive forum provision in the Certificate of Incorporation could limit stockholders' ability to obtain a favorable judicial forum for disputes.
• Recent and future changes to tax laws could materially adversely affect the company.
• Securities litigation is expensive and could divert management attention.
• Significant increased costs as a public company, requiring substantial management time and resources for new compliance initiatives.
• Future issuance of equity or debt securities convertible into equity would dilute share capital.
• Sales of a substantial number of shares by existing stockholders in the public market could cause stock price to fall.
• Techniques employed by short sellers may drive down the market price of common stock.
• As an emerging growth company and a smaller reporting company, election of reduced reporting requirements may make common stock less attractive to investors.
• Failure to comply with Nasdaq's continued listing requirements could result in a delisting of common stock.
• Unfavorable global economic or political conditions could adversely affect business, financial condition, or results of operations.

Future Outlook

The company expects expenses and operating losses to increase substantially for the foreseeable future as it continues the development, regulatory approval, and potential commercialization of ARD-101 and other product candidates. Topline data for the HERO clinical trial is anticipated in Q3 2026. The POWER trial is expected to initiate in H2 2025 with preliminary/interim data in H2 2026, and the STRENGTH trial is planned for H1 2026. Existing cash, cash equivalents, and short-term investments of $126.4 million are projected to fund operations into 2027, but substantial additional funding will be required to complete development and commercialization, likely through equity offerings, debt financings, or collaborations. Significant commercialization expenses are expected if product candidates are approved.

Management Comments

• "We believe its cash, cash equivalents and short-term investments of $126.4 million as of September 30, 2025 will be sufficient for the Company to continue as a going concern for at least one year following the date that the unaudited condensed consolidated financial statements are available to be issued."
• "The Company will be required to raise additional capital and plans to finance its cash needs through public or private equity or debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements."
• "If the Company is not able to secure adequate additional funding, it may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or delay or reduce the scope of its planned development programs. Any of these actions could materially harm the Company's business, results of operations and future prospects."
• "We believe that the design of the POWER trial will allow for more focused data generation to elucidate the potential of ARD-201 for preventing weight regain after GLP-1RA discontinuation."
• "We believe that the POWER and STRENGTH trials will enhance the probability of detecting potential clinical benefit with better clarity and precision than the trial design for the previously contemplated EMPOWER trial."
• "We have identified a material weakness in our internal control over financial reporting. If we fail to remediate this material weakness, or if we experience additional material weaknesses in the future or otherwise fail to maintain effective internal control over financial reporting in the future, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect investor confidence in us and, as a result, the value of our common stock."

Industry Context

Aardvark Therapeutics operates in the highly competitive biopharmaceutical sector, focusing on metabolic diseases and hunger-associated conditions. Its novel approach targeting Bitter Taste Receptors (TAS2Rs) is in a rapidly evolving field, carrying inherent risks due to its unproven nature for marketable products. The company is addressing the rare disease Prader-Willi Syndrome (PWS) and the significant market of obesity and weight regain, where it faces established competitors like Eli Lilly and Novo Nordisk with GLP-1RA therapies. The industry is also navigating increasing governmental scrutiny over drug pricing and reimbursement, exemplified by the Inflation Reduction Act (IRA) in the U.S. and Health Technology Assessment (HTA) regulations in Europe, which could impact future profitability. Broader macroeconomic trends, geopolitical conflicts, and disruptions in regulatory agencies (FDA, SEC) further influence industry operations and access to capital.

Comparison to Industry Standards

• For hyperphagia associated with PWS, Soleno Therapeutics' VYKAT XR is the only approved treatment, while competitors like Rhythm Pharmaceuticals, Relmada Therapeutics, and Bright Minds Biosciences Inc. also have therapeutic candidates in development.
• For obesity and obesity-related conditions, Aardvark Therapeutics competes with major pharmaceutical companies including Eli Lilly, Novo Nordisk, Roche, Pfizer, AstraZeneca, Boehringer Ingelheim, Amgen, Zealand Pharma, Viking Therapeutics, Altimmune, Terns Pharmaceuticals, Merck, and Structure Therapeutics.
• Preclinical data for ARD-201 showed significant weight loss (-18.8% ± 2.1% at 30 days) in DIO mice, and improved weight maintenance compared to vehicle control after transient tirzepatide treatment, with comparable weight maintenance to continued high-dose tirzepatide. The combination of ARD-201 and low-dose tirzepatide showed continued weight loss greater than high-dose tirzepatide alone, suggesting potential competitive advantages in weight management and glucose tolerance, particularly in preventing weight regain and enhancing GLP-1RA effects.
• The company's approach of targeting TAS2Rs is described as 'unproven' in the context of marketable products, indicating it's a novel mechanism compared to more established approaches in the biopharmaceutical industry.

Corporate Governance

Legal Proceedings

• Not presently a party to any legal proceedings that, in the opinion of management, would have a material adverse effect on the business, financial condition, or results of operations.
• The company accrues a liability for claims or suits when probable and estimable, but no material amounts have been accrued as of September 30, 2025.

Related Party Transactions

• Family members of the Chief Executive Officer are investors in the company, owning 1,975,323 shares of common stock as of September 30, 2025.
• The Chief Executive Officer is a member of the board of directors of Aardwolf Therapeutics, Inc.
• Unreimbursed costs incurred on behalf of Aardwolf Therapeutics, Inc. totaled $1.4 million as of September 30, 2025, and December 31, 2024. These costs have been deemed uncollectible and fully written off.
• A convertible promissory note with a principal amount of $1.0 million issued by Aardwolf Therapeutics, Inc. to the company in August 2022 was deemed uncollectible and written off in 2022.
• Aardwolf Therapeutics, Inc. is considered a variable interest entity (VIE), but the company is not deemed its primary beneficiary and thus has not consolidated its financial position or results of operations.

Stakeholder Impact

• Shareholders: Potential for dilution from future capital raises, stock price volatility, and reliance on capital appreciation as the sole source of gain due to no anticipated dividends. Anti-takeover provisions may limit acquisition opportunities.
• Employees: Expected increase in headcount, stock-based compensation opportunities through new incentive plans (2025 Plan, 2025 Inducement Plan, ESPP), and competition for qualified personnel in the industry.
• Customers (future patients): Potential for new therapeutic options for Prader-Willi Syndrome (ARD-101) and obesity/weight regain (ARD-201), with expanded eligibility for the ARD-101 trial.
• Suppliers/Vendors: Continued reliance on third-party contract manufacturers and CROs for clinical supplies and trial conduct, with risks related to performance, regulatory compliance, and supply chain disruptions.
• Creditors: Potential for future debt financings, but existing related party debt (Aardwolf note) has been written off as uncollectible.

Next Steps

• Continue development of ARD-101 and other product candidates.
• Seek regulatory approval for ARD-101 and other product candidates.
• Potentially commercialize ARD-101 and other product candidates if approved.
• Discover and develop additional product candidates.
• Conduct ongoing and planned clinical trials and preclinical studies, including the HERO, POWER, and STRENGTH trials.
• Utilize third parties to manufacture ARD-101 and other product candidates and related raw materials.
• Hire additional personnel, particularly in clinical development, product development, manufacturing, regulatory affairs, quality assurance, and potentially sales and marketing.
• Maintain, expand, and protect the intellectual property portfolio.
• Implement operational, financial, and management information systems.
• Remediate the identified material weakness in internal control over financial reporting by hiring additional experienced accounting and financial reporting personnel, formalizing internal controls, and implementing a new enterprise resource planning system.
• An Independent Advisory Review Committee will conduct an interim analysis for the HERO trial to assess if an increase in sample size is warranted.
• Initiate the POWER trial in the second half of 2025.
• Initiate the STRENGTH trial in the first half of 2026.
• Anticipate topline data for the HERO clinical trial in the third quarter of 2026.
• Anticipate preliminary or interim data for the POWER trial in the second half of 2026.
• Bryan Jones's Rule 10b5-1 trading arrangement permits transactions through March 31, 2026.

Key Dates

Recommendation

Aardvark Therapeutics is a clinical-stage biopharmaceutical company with no revenue and significant losses, which is typical for its stage. The initiation of a pivotal Phase 3 trial for ARD-101 in PWS and the promising preclinical data for ARD-201 in obesity are strong positive developments, indicating progress towards potential commercialization. The company's cash runway into 2027 provides a reasonable period for continued development without immediate financing pressure. However, the inherent high risks of drug development, including uncertain clinical trial outcomes, regulatory hurdles, and intense competition, remain significant. The identified material weakness in internal controls, while being addressed, adds an element of operational risk. Given the early stage of product candidates and the long path to profitability, a 'Hold' recommendation is appropriate, acknowledging the potential upside from clinical success balanced by the substantial risks and the need for future capital.

Keywords

Biopharmaceutical, Clinical-stage, Metabolic Diseases, Hyperphagia, Prader-Willi Syndrome, PWS, ARD-101, ARD-201, TAS2Rs, Bitter Taste Receptors, Obesity, Weight Regain, GLP-1RA, DPP-4 Inhibitor, Clinical Trials, Phase 3, Phase 2, Drug Development, SEC Filing, 10-Q, Financial Results, R&D Expenses, Corporate Governance, Internal Controls, Intellectual Property